Bedrijfsoverzicht
Moderna, Inc. is a biotechnology enterprise that develops and delivers messenger RNA therapeutics and vaccines across the United States, Europe, and global markets, with its respiratory vaccine portfolio including products such as Spikevax and seasonal influenza formulations. Operating within the Healthcare sector and the Biotechnology industry, the company focuses on advancing mRNA technology to address respiratory diseases and other medical conditions. The firm employs approximately 4,700 individuals and holds a market capitalization of $20.21 billion, reflecting its status as a significant entity within the life sciences landscape. Its reported trailing twelve-month revenue stands at $1.94 billion, a figure that, when combined with its substantial market cap, indicates a valuation that is not solely anchored to current earnings but heavily weighted towards future potential and intellectual property value. The scale of operations, supported by a workforce of nearly five thousand employees, underscores the company's capacity to manage complex research and development pipelines while maintaining a broad geographic footprint for vaccine distribution.
Financiële gezondheid
Moderna generated $1.94 billion in revenue over the trailing twelve months, yet it reported a net loss of $2,822,000,128 and an EBITDA of $-2,859,000,064, highlighting a significant divergence between top-line sales and bottom-line profitability driven by high operational expenditures. This substantial gap between revenue and net income reveals a cost structure where expenses related to research, development, and manufacturing far exceed current sales proceeds, a common characteristic in the early-to-mid stages of biotechnology growth. The company generated free cash flow of $-1,326,499,968, indicating a net cash burn that necessitates continuous access to capital markets or existing liquidity reserves to sustain operations. Despite the negative cash flow, the balance sheet remains robust with $5.80 billion in cash and cash equivalents against total debt of $1.30 billion, providing a substantial liquidity buffer. The debt-to-equity ratio of 15.09 suggests a conservative capital structure with minimal leverage relative to equity, reducing the risk of financial distress during periods of cash burn. Furthermore, a current ratio of 3.29 demonstrates strong short-term liquidity, ensuring the company can easily meet its obligations as they come due without immediate refinancing risks. Return on Equity stands at -28.9% and Return on Assets is -14.5%, metrics that indicate management is currently deploying capital into high-cost initiatives that have not yet translated into positive returns, which is typical for firms investing heavily in clinical trials and regulatory approvals.
Waarderingsbeoordeling
Moderna's valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to losses and a forward P/E of -10.96, implying that traditional earnings-based valuation models are currently inapplicable and that the market is pricing in future earnings recovery rather than current performance. The price-to-book ratio of 2.32 indicates that the market values the company at more than double its book value, suggesting a premium assigned to its intangible assets, proprietary mRNA platforms, and potential pipeline value. Additionally, the price-to-sales ratio of 10.40 and an EV/EBITDA of -5.47 further illustrate that investors are valuing the firm based on revenue generation and strategic potential rather than immediate profitability. The stock has exhibited significant volatility, trading between a 52-week high of $59.55 and a 52-week low of $22.28, which defines a trading range of $37.27. Relative to this range, the current price sits at a position that reflects ongoing market uncertainty regarding the commercialization of new vaccine candidates and the longevity of demand for respiratory influenza vaccines. The beta of 1.34 signifies that the stock is 34% more volatile than the broader market, exposing investors to heightened price swings that may amplify both gains and losses during periods of market stress.
Growth & Income
Moderna's revenue growth year-over-year has contracted by 29.8%, while earnings growth is N/A due to the absence of net income, a dynamic where the lack of earnings growth is directly correlated with the sharp decline in revenue and ongoing operational losses. The absence of a dividend yield and a payout ratio of 0.0% confirms that the company does not distribute profits to shareholders, as there are no profits to distribute. Instead, the firm retains all generated cash to fund its extensive research and development efforts, clinical trials, and manufacturing scale-up required to bring new mRNA medicines to market. This reinvestment strategy prioritizes long-term technological advancement and market expansion over providing immediate income to investors, which is a standard approach for biotechnology companies with promising but unproven future cash flows.